GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT07611201

Completed

The Effects of GLP-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior

The Effects of GLP-1 Receptor Agonists on Sensory Systems and Ingestive Behavior

Lead sponsor

Purdue University

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoints

•Taste Detection Thresholds•Suprathreshold Taste Intensity•Taste Hedonics

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07611201

Org study IDIRB-2024 - 1407

Timeline

Milestones

Study start2025-02-20actual

Primary completion2026-05-04actual

Study completion2026-05-04actual

Study first posted2026-05-28actual

Last update posted2026-05-28actual

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Sampling methodNon probability sample

Study population text

Adults aged 18 to 65 years with a Body Mass Index (BMI) greater than 30 kg/m² will be recruited. The study population includes individuals who are eligible to take GLP-1 receptor agonists but have not yet started treatment, and individuals who have been taking GLP-1 receptor agonists for weight management for approximately 1 month or approximately 6 months as part of their regular medical care. Participants will be recruited from the general population and through healthcare providers at IU Health.

Inclusion criteria

•Ages 18 to 65 years.

•Any sex or gender.

•Body Mass Index (BMI) >30 kg/m².

•Stable medication use, excluding weight management medications other than GLP-1 receptor agonist use as part of regular medical care.

•Eligible to take GLP-1 receptor agonists but not yet started treatment, or currently taking GLP-1 receptor agonists for weight management for approximately 1 month (±0.5 months) or approximately 6 months (±0.5 months).

•No known sensitivity or allergy to study solutions or foods, including sweet solutions, salty solutions, sour solutions, bitter solutions, fatty stimuli, common food flavors used in testing, milk, and fruit-flavored beverages.

Exclusion criteria

•Younger than 18 years or older than 65 years.

•Previous bariatric surgery or planned bariatric surgery within the next year.

•Sensitivity or allergy to study foods, taste solutions, odor stimuli, or food-related test materials.

Endpoints (11)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Patient-reported / QoL

2 endpoints

Secondary/protocol endpoint

Food Preferences